X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-expanded-use-beigenes-blood-cancer-drug-2024-03-07/
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-zanubrutinib-capsules-93626.pdf
https://www.ema.europa.eu/en/documents/overview/brukinsa-epar-medicine-overview_en.pdf
https://www.biospectrumasia.com/news/25/23378/singapores-cancer-drug-list-adds-beigenes-zanubrutinib-for-multiple-indications.html
https://endpts.com/in-early-look-at-ash-abstracts-beigene-touts-brukinsa-data-cellectis-compares-in-house-car-t-to-cdmo-car-t/
https://www.onclive.com/view/zanubrutinib-sustains-response-safety-benefits-vs-ibrutinib-in-waldenstr-m-macroglobulinemia
https://www.fiercepharma.com/pharma/abbvies-imbruvica-brukinsa-patent-suit-may-have-merit-and-beigene-will-likely-settle-expert
https://www.onclive.com/view/long-term-rosewood-data-confirm-efficacy-of-zanubrutinib-plus-obinutuzumab-in-r-r-follicular-lymphoma
https://www.onclive.com/view/zanubrutinib-plus-obinutuzumab-and-venetoclax-induces-high-undetectable-mrd-rate-in-cll-sll
https://ir.beigene.com/news/beigene-highlights-significant-brukinsa-zanubrutinib-data-at-the-17th-international-conference-on-malignant-lymphoma/c1b14dea-5362-4fde-92cc-b96b84811719/
https://www.fiercepharma.com/pharma/beigene-offers-brukinsa-cll-patients-29-low-income-countries-through-max-foundation
https://www.pharmaceutical-technology.com/news/china-nmpa-beigene-brukinsa/
https://www.fiercepharma.com/pharma/beigene-doubles-sales-brukinsa-tislelizumab-gear-key-launches
https://www.ema.europa.eu/en/documents/overview/brukinsa-epar-medicine-overview_en.pdf
https://www.businesswire.com/news/home/20230119005082/en/BRUKINSA%C2%AE-zanubrutinib-Receives-Marketing-Authorization-for-Chronic-Lymphocytic-Leukemia-CLL-and-Marginal-Zone-Lymphoma-MZL-in-Great-Britain-by-MHRA
https://ir.beigene.com/news/brukinsa-zanubrutinib-receives-marketing-authorization-for-chronic-lymphocytic-leukemia-cll-and-marginal-zone-lymphoma-mzl/a8a3a661-0497-4696-b763-e3ffef2de63b/
https://www.businesswire.com/news/home/20221213005484/en/%C2%A0BeiGene%E2%80%99s-BRUKINSA%C2%AE-zanubrutinib-Demonstrated-Superior-Progression-Free-Survival-Over-IMBRUVICA%C2%AE-ibrutinib-in-Chronic-Lymphocytic-Leukemia-in-Late-Breaker-at-ASH
https://www.fiercepharma.com/marketing/beigene-wants-greater-blending-mental-health-cancer-care-new-survey-reveals-worrying-gaps
https://ir.beigene.com/news/beigene-to-present-final-pfs-results-from-alpine-trial-demonstrating-superior-pfs-for-brukinsa-versus-imbruvica-in/3eaa7080-547b-4792-a670-a496e02046f4/
https://ir.beigene.com/news/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-marginal/66b2b907-4d3c-466f-836d-43e225f2a7b2/
https://www.thepharmaletter.com/article/beigene-gains-further-approvals-for-brukinsa-in-latin-america
https://ir.beigene.com/news/beigene-expands-reach-of-its-innovative-btk-inhibitor-with-recent-regulatory-approvals-in-latin-america/90d9b3ec-8231-484c-aa89-0df0f6bebb46/
https://www.fiercepharma.com/pharma/beigene-heaps-more-pressure-abbvie-and-jj-new-brukinsa-imbruvica-head-head-win
https://www.pharmaceutical-technology.com/news/nice-zanubrutinib-waldenstroms-macroglobulinaemia/
https://pharmaphorum.com/news/nice-says-yes-to-beigenes-brukinsa-after-scottish-nay/
https://www.fiercepharma.com/pharma/beigene-keeps-momentum-going-brukinsa-winning-nice-recommendation-wm
https://www.fiercepharma.com/pharma/short-reprieve-abbvie-and-jj-fda-extends-beigenes-brukinsa-review-blockbuster-leukemia-realm
https://www.ema.europa.eu/en/documents/overview/brukinsa-epar-medicine-overview_en.pdf
http://www.pharmafile.com/news/604795/supplemental-nda-accepted-leukaemia-treatment-china
https://ir.beigene.com/news-details/?id=bd70a6d2-35e1-4fcb-a5de-cf202c9c8acc
Market Place
Share 
